v3.26.1
Revenue (Tables)
6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of amounts were recognized within revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended June 30, 

​

Six Months Ended June 30, 

(In thousands)

​

2026

​

2025

​

2026

​

2025

Viatris collaboration agreement – Amounts receivable from Viatris

​

$

20,731

​

$

18,695

​

$

38,430

​

$

34,083

Licensing revenue – China Region regulatory approval milestone

​

​

—

​

​

7,500

​

​

—

​

​

7,500

Total

​

$

20,731

​

$

26,195

​

$

38,430

​

$

41,583

 

Schedule of implied share of total net sales

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended June 30, 

​

Six Months Ended June 30, 

(In thousands)

  ​

2026

  ​

2025

  ​ ​ ​

2026

  ​

2025

YUPELRI net sales (Theravance Biopharma implied 35%)

​

$

24,733

​

$

23,216

​

$

46,584

​

$

43,636